In patients with high-risk melanoma, the personalized cancer vaccine intismeran autogene and Keytruda reduced the risk of ...

Shares of Moderna MRNA were up 15.8% on Jan. 21, after the company and its partner Merck MRK announced positive median ...

The healthcare giant just took a major step that could reshape its MedTech business and boost its dividend track record.

Moderna & Merck announce 5-year data for intismeran autogene in combo with Keytruda demonstrated sustained improvement in primary endpoint of recurrence-free survival in patients with high-risk stage ...

Moderna and Merck shared five-year study data showing their combined cancer treatment cut the risk of melanoma coming back or ...

Intismeran autogene with pembrolizumab shows a 49% reduction in recurrence or death risk in patients with high-risk resected melanoma over 5 years. The personalized mRNA therapy targets ...

I've always been slim, but a couple of years ago I noticed that the size of my breasts has increased and that I have put ...

Skin cancer is one of the most common cancers in the US, with melanoma accounting for the majority of skin cancer deaths ...

The positive long-term data represents a significant milestone for Moderna as it works to diversify its revenue beyond COVID-19 vaccines and establish its mRNA platform as a viable cancer treatment ...

Doctors at Fortis Escorts Okhla, New Delhi, have accomplished a remarkable surgical feat: a multidisciplinary team led by Dr ...

Moderna stock rose over 7% after the company and Merck said their personalized melanoma vaccine kept working at five years, cutting recurrence or death risk by 49%.